Abstract Between 10% and 40% of newly diagnosed patients with acute myeloid leukemia
(AML) do not achieve complete remission with intensive induction therapy and are therefore …

Although the identification of cancer stem cells as therapeutic targets is now actively being
pursued in many human malignancies, the leukemic stem cells in acute myeloid leukemia …

Background The results of the addition of gemtuzumab ozogamicin, an anti-CD33 antibody
conjugate, to the standard treatment for patients with acute myeloid leukaemia in phase 3 …

Conventional cancer chemotherapy heavily relies on the use of cytotoxic agents, which
typically do not preferentially localize at the tumor site and cause toxicity to normal organs …

CD33 is a myeloid differentiation antigen with endocytic properties. It is broadly expressed
on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has …

Immunotherapy has revolutionized therapy in both solid and liquid malignancies. The ability
to cure acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an …

Simple Summary Roughly 85–90% of adult and pediatric acute myeloid leukemia (AML) are
CD33-positive. Gemtuzumab ozogamicin (GO), a humanized murine IgG4 anti-CD33 …

To provide data for future drug evaluation, we analyzed the outcome of 393 patients aged 50
years or older (median, 64 years) with AML in first relapse after treatment in recent ALFA …

Antibodies have created high expectations for effective yet tolerated therapeutics in acute
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …

Background Epigenetic therapeutics such as the histone deacetylase (HDAC) inhibitor,
vorinostat, and the DNA methyltransferase (DNMT) I inhibitor, azacitidine, sensitize AML …